European Meeting on HIV & Hepatitis 2021

COVID-19 in People Living with HIV- Anna Maria Geretti, MD, PhD, FRCPath

Video

HIV

Viral Hepatitis and Liver Disease

Integrating New HIV Treatments in the COVID-19 Era- Chloe Orkin, MBChB, FRCP, MD,

Video

HIV

Viral Hepatitis and Liver Disease

Improving European Healthcare - Lessons Learned from the COVID-19 Pandemic - Dominique Costagliola, PhD

Video

HIV

Viral Hepatitis and Liver Disease

The Top 10 Important Observations of the Last Year Affecting Clinical Management - Valentina Svicher, PhD

Video

HIV

Viral Hepatitis and Liver Disease

Prevention- Richard Elion, MD

Video

HIV

Viral Hepatitis and Liver Disease

Treatment- Giuliano Rizzardini, MD

Video

HIV

Viral Hepatitis and Liver Disease

Gilead- Kirsten White, PhD

Video

HIV

Viral Hepatitis and Liver Disease

Interaction Subtypes and New Drugs- Charlotte Charpentier, PharmD, PhD

Video

HIV

Viral Hepatitis and Liver Disease

Characterization of SARS-CoV-2 variants circulating in Central Italy by deep-sequencing of full-length S gene - Maria Bellocchi,

Video

HIV

Viral Hepatitis and Liver Disease

Molecular epidemiology of SARS-CoV-2 in Greece reveals low rates of onward virus transmission after lifting of travel restrictions based on risk assessment during summer 2020- Evangelia Georgia Kostaki, PhD

Video

HIV

Viral Hepatitis and Liver Disease

Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers - Stéphane Marot, MD

Video

HIV

Viral Hepatitis and Liver Disease

LONG-ACTING HIV CAPSID INHIBITOR EFFECTIVE AS PREP IN A SHIV RHESUS MACAQUE MODEL- Elena Bekerman, PhD

Video

HIV

Viral Hepatitis and Liver Disease

"Prevalence of genotypic baseline risk factors of cabotegravir+rilpivirine failure among ARV-naïve patients "- Charlotte Charpentier, PharmD, PhD

Video

HIV

Viral Hepatitis and Liver Disease

HIV-1 Subtypes B, G and CRF02_AG Transmission Cluster in Migrants Population Followed in Portugal Based on Sequence Data - Victor Pimentel

Video

HIV

Viral Hepatitis and Liver Disease

Low Prevalence of Archived M184V/I Mutations in 3 HIV-1 Suppressed, Switch Studies- Ruolan Wang

Video

HIV

Viral Hepatitis and Liver Disease

Kinetics of Archived M184V Mutation in HIV-DNA from Highly Experienced HIV-Infected Patients with Sustained Viral Suppression - Romain Palich, MD

Video

HIV

Viral Hepatitis and Liver Disease

HIV-1Reverse Transcriptase Natural Polymorphism V106I Does Not Alter the Susceptibility and the Genetic Barrier to Resistance to Doravirine in Vitro - Federica Giammarino, MD

Video

HIV

Viral Hepatitis and Liver Disease

Exploratory Analysis of Baseline Phenotypic and Genotypic Parameters in Relation to Antiviral Activity for Fostemsavir (FTR) in Heavily Treatment-Experienced (HTE) Patients in the Phase 3 BRIGHTE Study - Margaret Gartland

Video

HIV

Viral Hepatitis and Liver Disease

Determinants of HIV-1 Late Presentation in Patients Followed in Europe- Mafalda Miranda, MD

Video

HIV

Viral Hepatitis and Liver Disease

Exploration of the Possible Mechanisms Leading to Greater Mortality in People with Limited Drug Options (LDO) - Alessandro Cozzi-Lepri, MD

Video

HIV

Viral Hepatitis and Liver Disease

Dynamics of Total and Intact HIV-1 DNA in in Virologically Suppressed Patients Switching to DTG+3TC or ATV/r+3TC Dual Therapy - Filippo Dragoni, MD

Video

HIV

Viral Hepatitis and Liver Disease

APOBEC Editing in HIV DNA Proviral Vif and Pol Long-Reads Issued from Virologically-Suppressed Patients Included in the ANRS LAMIDOL Trial - Charlotte Charpentier, PharmD, PhD

Video

HIV

Viral Hepatitis and Liver Disease

Usefulness of Next-Generation Sequencing on PBMC Samples and HIV-1 DNA Quantification in Management of Treatment Optimization in HIV-1 Infected Virologically Suppressed Individuals - Daniele Armenia

Video

HIV

Viral Hepatitis and Liver Disease

A Comprehensive Molecular Epidemiological Analysis of SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic - Andreas Chrysostomou, MSc

Video

HIV

Viral Hepatitis and Liver Disease

Abstract - Driven Presentations I

Video

HIV

Viral Hepatitis and Liver Disease

Andrea Del Luca Lecture & Roundtable debate

Video

HIV

Viral Hepatitis and Liver Disease

European Meeting on HIV & Hepatitis 2021

COVID-19 in People Living with HIV- Anna Maria Geretti, MD, PhD, FRCPath

Integrating New HIV Treatments in the COVID-19 Era- Chloe Orkin, MBChB, FRCP, MD,

Improving European Healthcare - Lessons Learned from the COVID-19 Pandemic - Dominique Costagliola, PhD

HBV - Cure - Fabien Zoulim, MD, PhD

HBV - Treatment- Maria Buti, MD, FAASLD

Impact on Vaccine Efficacy- Ravindra Gupta, MD, PhD

Update on Therapeutics Options- Roger Paredes, MD, PhD

ViiV- Harmony Garges, MD, MPH

Impact on Diagnostics and Treatment- Francesca Ceccherini- Silberstein, PhD

The Top 10 Important Observations of the Last Year Affecting Clinical Management - Valentina Svicher, PhD

Prevention- Richard Elion, MD

Treatment- Giuliano Rizzardini, MD

Gilead- Kirsten White, PhD

Interaction Subtypes and New Drugs- Charlotte Charpentier, PharmD, PhD

Characterization of SARS-CoV-2 variants circulating in Central Italy by deep-sequencing of full-length S gene - Maria Bellocchi,

Molecular epidemiology of SARS-CoV-2 in Greece reveals low rates of onward virus transmission after lifting of travel restrictions based on risk assessment during summer 2020- Evangelia Georgia Kostaki, PhD

Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers - Stéphane Marot, MD

LONG-ACTING HIV CAPSID INHIBITOR EFFECTIVE AS PREP IN A SHIV RHESUS MACAQUE MODEL- Elena Bekerman, PhD

"Prevalence of genotypic baseline risk factors of cabotegravir+rilpivirine failure among ARV-naïve patients "- Charlotte Charpentier, PharmD, PhD

HIV-1 Subtypes B, G and CRF02_AG Transmission Cluster in Migrants Population Followed in Portugal Based on Sequence Data - Victor Pimentel

Low Prevalence of Archived M184V/I Mutations in 3 HIV-1 Suppressed, Switch Studies- Ruolan Wang

Kinetics of Archived M184V Mutation in HIV-DNA from Highly Experienced HIV-Infected Patients with Sustained Viral Suppression - Romain Palich, MD

HIV-1Reverse Transcriptase Natural Polymorphism V106I Does Not Alter the Susceptibility and the Genetic Barrier to Resistance to Doravirine in Vitro - Federica Giammarino, MD

Exploratory Analysis of Baseline Phenotypic and Genotypic Parameters in Relation to Antiviral Activity for Fostemsavir (FTR) in Heavily Treatment-Experienced (HTE) Patients in the Phase 3 BRIGHTE Study - Margaret Gartland

Determinants of HIV-1 Late Presentation in Patients Followed in Europe- Mafalda Miranda, MD

Exploration of the Possible Mechanisms Leading to Greater Mortality in People with Limited Drug Options (LDO) - Alessandro Cozzi-Lepri, MD

Dynamics of Total and Intact HIV-1 DNA in in Virologically Suppressed Patients Switching to DTG+3TC or ATV/r+3TC Dual Therapy - Filippo Dragoni, MD

APOBEC Editing in HIV DNA Proviral Vif and Pol Long-Reads Issued from Virologically-Suppressed Patients Included in the ANRS LAMIDOL Trial - Charlotte Charpentier, PharmD, PhD

Usefulness of Next-Generation Sequencing on PBMC Samples and HIV-1 DNA Quantification in Management of Treatment Optimization in HIV-1 Infected Virologically Suppressed Individuals - Daniele Armenia

A Comprehensive Molecular Epidemiological Analysis of SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic - Andreas Chrysostomou, MSc

Abstract - Driven Presentations I

Andrea Del Luca Lecture & Roundtable debate

Abstract - Driven Presentations II